Global Cell Therapy and Gene Therapy Market Report 2023-2029


Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029" report has been added to ResearchAndMarkets.com's offering.

A newly released report highlights noteworthy projections for the cell therapy and gene therapy markets from 2023 through 2029. This comprehensive analysis sheds light on a range of therapeutic areas, addressing market estimates, competitive landscape, and developmental pipelines of cell and gene therapies across different disease types.

Market Overview

The report details the paradigm-shift potential of cell and gene therapies, indicating a substantial surge in innovative treatments that are targeting genetic causes of diseases and harnessing the power of the immune system.

The emerging market sectors include oncology, neurology, musculoskeletal disorders, dermatology, cardiology, and other significant areas of medical concern.

Research and Development Trends

With escalating numbers of clinical trials and enhanced therapeutic strategies, the markets are expected to show continued growth. The report takes a deep dive into the current global developments in cell, gene, and RNA therapies, discussing principal products and overarching trends within the respective segments.

Regional Insights and Competitive Analysis

The comprehensive analysis offers a granular look at the market distribution and regional revenue patterns. A summary of the competitive landscape provides insight into the key players and their standings within each therapeutic area. By furnishing a thorough competitive situation summary, the report contributes valuable intelligence to stakeholders and participants in the healthcare industry.

Market Segmentation and Forecasting

The segmentation analysis provides overviews of various therapies, encompassing market estimates and forecasts that reflect the provider competitive situations. The report is meticulous in its investigation of therapies in development, projecting their impacts on future market trends up to the year 2029.

Market Potential and Forecast

While gene therapies have yet to achieve widespread availability, the report's forecasts are grounded in a cautious examination of the current pipeline and nascent market.

This forward-looking perspective estimates global market values for the year 2023 and anticipates the market landscape in 2029, outlining potential growth and opportunities in the cell and gene therapy sectors.

In conclusion, the industry report provides a significant resource for understanding the evolving landscapes of cell and gene therapies. Its findings underscore the expectation that the next six years will witness transformative growth and development within these cutting-edge segments of medical science.

Companies Featured

  • AlloSource
  • Alnylam Pharmaceuticals, Inc.
  • Amgen
  • AnGes Inc.
  • Anterogen Co Ltd.
  • Atara Biotherapeutics
  • Athersys, Inc
  • BioCardia
  • Biogen, Inc.
  • BioMarin Pharmaceuticals
  • bluebird bio, Inc.
  • BrainStorm Cell Therapeutics
  • Bristol-Myers Squibb
  • Candel Therapeutics
  • Castle Creek Biosciences
  • Celyad Oncology
  • Cook Myosite, Inc
  • Dendreon Pharmaceuticals (Sanpower)
  • FerGene, Inc (Ferring Pharmaceuticals)
  • Gamida Cell Ltd.
  • GenSight Biologics S.A.
  • Gilead Sciences, Inc.
  • Gradalis, Inc
  • Helixmith
  • Inovio Pharmaceuticals, Inc.
  • Kiadis Pharma B.V. (Sanofi)
  • Medeor Therapeutics
  • MEDIPOST Co, Ltd.
  • MeiraGTx
  • Mesoblast Ltd.
  • Northwest Biotherapeutics, Inc.
  • Novartis AG
  • NuVasive Biologics
  • Orchard Therapeutics
  • Organogenesis
  • Orthofix
  • Osiris Therapeutics, Inc. (part of Smith & Nephew)
  • Pharmicell
  • Pluristem Therapeutics, Inc.
  • Sangamo Therapeutics
  • Sanofi
  • Sarepta
  • Sotio a.s.
  • Spark Therapeutics
  • Tessa Therapeutics, Ltd.
  • uniQure N.V.
  • Vericel Corporation

Key Topics Covered:

CHAPTER 1: EXECUTIVE SUMMARY

  • Scope and Methodology
  • Market Overview and Potential

CHAPTER 2: INTRODUCTION TO CELL AND GENE THERAPY

  • Cell Therapy
  • CAR T
  • Stem Cells
  • Adult Stem Cells
  • Human Embryonic Stem Cells
  • Gene Therapy
  • Viral Vector System and New Developments
  • Non-viral Systems for Transporting Genes
  • Gene Editing
  • Cell and Gene Therapy: Characteristics
  • Staffing
  • Manufacturing Process for CAR-T
  • Leukapheresis
  • Activation
  • Transduction
  • Expansion
  • Cell and Gene Therapy Manufacturing Processes
  • Cost
  • Reimbursement
  • Logistics
  • Mergers and Acquisitions
  • Deals, Agreements, and Collaborations
  • Regulatory Developments
  • Fast Track
  • Orphan Drug
  • Breakthrough Therapy
  • Accelerated Approval
  • Priority Review
  • Individualized Gene Therapy Approval Process
  • Pipeline, Development Overview
  • Pipeline, Development Progress
  • Pipeline by Condition and Therapeutic Area
  • Phase III Development
  • End Users
  • Hospitals
  • Research Institutes
  • Wound Care Centers
  • Cancer Centers

CHAPTER 3: CELL AND GENE THERAPY MARKETS IN ONCOLOGY

  • Biochemistry of Cancer Cells
  • Causes of Cancer Growth
  • Environmental Factors, DNA, RNA
  • Cellular Oncogenes
  • Tumor Suppressor Genes
  • Global Cancer Burden
  • Market Outlook
  • Principal Products
    • Abecma
    • APCeden
    • Breyanzi
    • Carvykti
    • CreaVax-RCC
    • Delytact
    • Gendicine
    • Imlygic
    • Immuncell-LC
    • Kymriah
    • Provenge
    • Tecartus
    • Yescarta
  • Trends in Research and Development
  • Phase III Development
  • Market Breakdown of Cell and Gene Therapies
  • Oncology Cell and Gene Therapy Market by Cancer Type
  • Regional Market Summary
  • Competitor Summary

CHAPTER 4: CELL AND GENE THERAPY MARKETS IN NEUROLOGICAL-RELATED DISORDERS

  • Market Outlook
  • Principal Products
    • Amvuttra
    • Libmeldy/ Lenmeldy
    • NeuroNata-R
    • Onpattro
    • SKYSONA
    • Spinraza
    • Stemirac
    • Wainua
    • Zolgensma
  • Trends in Research and Development
  • Phase III Development
  • Market Breakdown of Cell and Gene Therapies
  • Regional Market Summary
  • Competitor Summary

CHAPTER 5: CELL AND GENE THERAPY MARKETS IN MUSCULOSKELETAL CONDITIONS AND DISORDERS

  • Market Outlook
  • Principal Products
    • AlloStem
    • Amondys
    • BIO4
    • Carticel
    • Cartiform
    • CartiLife
    • Cartistem
    • Chondron
    • Elevidys
    • Exondys
    • JACC
    • MACI
    • Ortho-ACI and Ortho-ATI
    • Ossron
    • Osteocel and Osteoplus
    • Spherox
    • Trinity Elite and Trinity Evolution
    • Vyondys
  • Trends in Research and Development
  • Phase III Development
  • Market Breakdown of Cell and Gene Therapies
  • Musculoskeletal Cell and Gene Therapy Market by Indication
  • Regional Market Summary
  • Competitor Summary

CHAPTER 6: CELL AND GENE THERAPY MARKETS IN DERMATOLOGY

  • Market Outlook
  • Principal Products
    • Adipocel
    • Apligraf
    • CureSkin
    • Dermagraft
    • Epicel
    • Grafix
    • Holoderm
    • Kaloderm
    • KeraHeal/KeraHeal-Allo
    • LaViv
    • Orcel
    • Quencell
    • RECELL
    • Rosmir
    • Stempeutics/Cutisera
    • StrataGraft
    • Stravix
    • TransCyte
    • Vyjuvek
  • Trends in Research and Development
  • Phase III Development
  • Market Breakdown of Cell and Gene Therapies
  • Dermatology Cell and Gene Therapy Market by Indication
  • Regional Market Summary
  • Competitor Summary

CHAPTER 7: CELL AND GENE THERAPY MARKETS IN CARDIOVASCULAR AND BLOOD DISORDERS

  • Cardiovascular Disease
  • Selected Blood Disorders
  • Market Outlook
  • Principal Products
    • Collategene
    • Hearticellgram
    • HeartSheet
    • Leqvio
    • Neovasculgen
    • Stempeucel
    • Zynteglo
  • Phase III Development
  • Market Breakdown of Cell, Gene, and RNA Therapies
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication
  • Regional Market Summary
  • Competitor Summary

CHAPTER 8: CELL AND GENE THERAPY MARKETS IN OTHER CONDITIONS

  • Market Outlook
  • Principal Products
    • Alofisel
    • Cupistem
    • Givlaari
    • Glybera
    • Holoclar
    • Luxturna
    • Oxlumo
    • Rethymic
    • Strimvelis
    • Temcell/Prochymal/Ryoncil
  • Trends in Research and Development
  • Market Breakdown of Cell and Gene Therapies
  • Regional Market Summary
  • Competitor Summary

CHAPTER 9: CELL AND GENE THERAPY MARKET REVIEW

  • Market Influences
  • Global Demographics
  • Aging Population
  • Cost Containment
  • Cell and Gene Therapy and Viral Vector Shortages
  • Global Market Summary
  • Cell vs. Gene Therapy Markets
  • Regional Market Overview
  • Competitor Ranking in Cell and Gene Therapy Markets

CHAPTER 10: MARKET PARTICIPANTS

For more information about this report visit https://www.researchandmarkets.com/r/leqezh

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

 

Coordonnées